Deutsche Bank reiterated their buy rating on shares of Qiagen (NYSE:QGEN) in a research note published on Friday morning, Borsen Zeitung reports.
Other analysts have also recently issued reports about the company. UBS Group started coverage on Qiagen in a research note on Friday, March 15th. They issued a neutral rating and a $42.00 price target on the stock. Jefferies Financial Group restated a neutral rating on shares of Qiagen in a research note on Monday, January 21st. Finally, Zacks Investment Research cut Qiagen from a hold rating to a sell rating in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $41.17.
Shares of NYSE QGEN opened at $40.45 on Friday. The firm has a market capitalization of $9.25 billion, a PE ratio of 30.19, a P/E/G ratio of 2.32 and a beta of 0.92. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.05 and a current ratio of 2.22. Qiagen has a 12-month low of $31.93 and a 12-month high of $41.55.
Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Monday, February 4th. The company reported $0.40 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.40. Qiagen had a return on equity of 12.15% and a net margin of 12.68%. The company had revenue of $403.20 million for the quarter, compared to analysts’ expectations of $409.32 million. During the same period last year, the firm earned $0.43 earnings per share. Qiagen’s quarterly revenue was up 1.6% on a year-over-year basis. As a group, analysts anticipate that Qiagen will post 1.45 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Lindbrook Capital LLC acquired a new stake in shares of Qiagen during the fourth quarter worth about $25,000. Captrust Financial Advisors increased its position in shares of Qiagen by 165.3% during the fourth quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock worth $35,000 after purchasing an additional 628 shares in the last quarter. Bremer Trust National Association acquired a new stake in shares of Qiagen during the fourth quarter worth about $45,000. Truvestments Capital LLC acquired a new stake in shares of Qiagen during the first quarter worth about $67,000. Finally, Fort L.P. acquired a new stake in shares of Qiagen during the fourth quarter worth about $68,000. Institutional investors and hedge funds own 64.77% of the company’s stock.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Article: Range Trading
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.